Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects
نویسندگان
چکیده
منابع مشابه
Teriflunomide for the treatment of multiple sclerosis.
Teriflunomide is a new active drug which has recently been approved as a first-line treatment of relapsing forms of MS in the US, Australia, Argentina, and the European Union. It is characterized by a once-daily oral application and a well-established long-term safety profile. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine in p...
متن کاملMRI in multiple sclerosis: current status and future prospects.
Many promising MRI approaches for research or clinical management of multiple sclerosis (MS) have recently emerged, or are under development or refinement. Advanced MRI methods need to be assessed to determine whether they allow earlier diagnosis or better identification of phenotypes. Improved post-processing should allow more efficient and complete extraction of information from images. Magne...
متن کاملPromoting remyelination in multiple sclerosis: current drugs and future prospects.
Myelin destruction due to inflammatory oligodendrocyte cell damage or death in conjunction with axonal degeneration are among the major histopathological hallmarks of multiple sclerosis (MS). The majority of available immunomodulatory medications for MS are approved for relapsing-remitting (RR) MS, for which they reduce relapse rate, MRI measures of inflammation, and the accumulation of disabil...
متن کاملTreatment of relapsing-remitting multiple sclerosis: current and future algorithms.
term outcomes. A long-term study examined survival in a cohort of patients (n = 372) who had participated in a pivotal randomized, placebo-controlled clinical trial of interferon beta in relapsing-remitting MS [5] . After a median of 21.1 years from the time of enrollment, 98% of patients were identified and 81 deaths were recorded. Early treatment was associated with prolonged survival, as evi...
متن کاملAn update of teriflunomide for treatment of multiple sclerosis
There are a number of oral agents emerging as potential disease-modifying agents in multiple sclerosis (MS). Among these investigational agents, teriflunomide has shown promise in large, multicenter, phase III clinical trials with respect to safety and efficacy in relapsing MS patients, and is the latest disease-modifying agent approved for use in MS patients in the United States. This review w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Neurological Disorders
سال: 2014
ISSN: 1756-2864,1756-2864
DOI: 10.1177/1756285614546855